A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Sitravatinib (Primary) ; Tislelizumab (Primary)
- Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Proof of concept
- Sponsors BeiGene
- 05 Dec 2019 Planned number of patients changed from 140 to 200.
- 05 Dec 2019 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 05 Dec 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Aug 2021.